DocWire News Editors

DocwireNews

Infusing&nbsp;a novel&nbsp;mimetic preparation (MDCO-216) with a statin did not stop the progression of&nbsp;coronary atherosclerosis compared to placebo in statin-treated patients with acute coronary syndromes, according to a new study published online in&nbsp;JAMA Cardiology. The double-blind, randomized trial included 122 statin-treated patients with acute coronary syndrome (113 of whom had evaluable imagine results at follow-up), who were either given 5 infusions of 20 mg/kg&nbsp;MDCO-216 (n=59) or placebo (n=67). The primary efficacy measure was nominal change in percent atheroma volume&nbsp;out to 36 days.&nbsp;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
same MoA, same (abscence of) effect&hellip; with MDCO-216 (presented at AHA 2016 if I remember well)
Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease<a href="https://t.co/hc9UoUvEnR">https://t.co/hc9UoUvEnR</a>
&mdash; Bertrand Delsuc (@BertrandBio) <a href="https://twitter.com/BertrandBio/status/1022524748998291456?ref_src=twsrc%5Etfw">July 26, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>According to the study results, decrease in atheroma volume was 0.94% in the MDCO group and 0.21% in the placebo group (95% CI, &minus;0.07 to 1.52; P=0.07). They researchers also reported a decrease in HDL-C levels in the MDCO group versus placebo (P&lt;0.001), no difference in the normalized&nbsp;decrease of total atheroma volume (P=0.67), and no differences in atheroma volume in the sickest segment of the patient population (P=0.83).&nbsp;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
HDL mimetic infusions fail to induce plaque regression in patients with acute coronary syndrome (again).<a href="https://t.co/WCg2pMJ6qS">https://t.co/WCg2pMJ6qS</a> <a href="https://twitter.com/JAMACardio?ref_src=twsrc%5Etfw">@JAMACardio</a>
&mdash; Benoit Arsenault (@ArsenaultBenoit) <a href="https://twitter.com/ArsenaultBenoit/status/1022150490237415424?ref_src=twsrc%5Etfw">July 25, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
HDL focused interventions keep coming up short. <a href="https://t.co/blV9NDIc5g">https://t.co/blV9NDIc5g</a>
&mdash; Jerad Dumolt, PhD, RD (@JeradDumolt) <a href="https://twitter.com/JeradDumolt/status/1022151201339654145?ref_src=twsrc%5Etfw">July 25, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&ldquo;This provides further disappointing news for the clinical development of therapies that target HDL in the setting of contemporary medical treatment for patients with coronary disease,&rdquo; the researchers concluded. &ldquo;Until such an agent does not prove to have beneficial effect on coronary&nbsp;atherosclerosis&nbsp;or clinical events, increasing interest will focus on alternative approaches to reducing&nbsp;residual&nbsp;cardiovascular risk.&rdquo;&nbsp;DocWire&nbsp;News has previously written on&nbsp;<a href="https://proddocwire.wpengine.com/cardiology/long-term-statin-remains-safe/">statins</a>,&nbsp;and on&nbsp;<a href="https://proddocwire.wpengine.com/cardiology/review-is-there-prognostic-value-in-heart-rate-recovery-in-cad-patients/">acute coronary&nbsp;syndromes.&nbsp;</a>Source:&nbsp;<a href="https://jamanetwork.com/journals/jamacardiology/fullarticle/2689022">JAMA Cardiology</a>&nbsp;

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

MILANO-PILOT: MDCO-216 Infusion Fails to Modify Plaque Regression

Lipid Management

Infusing a novel mimetic preparation (MDCO-216) with a statin did not stop the progression of coronary atherosclerosis compared to placebo in statin-treated patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe